A whole-food exclusion diet as monotherapy for Crohn's disease

Affiliations

¹ Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Electronic address: asasson@hsph.harvard.edu.

Comment

Alexa N Sasson. Lancet Gastroenterol Hepatol. 2022 Jan.

. 2022 Jan;7(1):6-7.

doi: 10.1016/S2468-1253(21)00335-6. Epub 2021 Nov 2.

¹ Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Electronic address: asasson@hsph.harvard.edu.

No abstract available

Conflict of interest statement

I declare no competing interests.

The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.
Yanai H, Levine A, Hirsch A, Boneh RS, Kopylov U, Eran HB, Cohen NA, Ron Y, Goren I, Leibovitzh H, Wardi J, Zittan E, Ziv-Baran T, Abramas L, Fliss-Isakov N, Raykhel B, Gik TP, Dotan I, Maharshak N. Yanai H, et al. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):49-59. doi: 10.1016/S2468-1253(21)00299-5. Epub 2021 Nov 2. Lancet Gastroenterol Hepatol. 2022. PMID: 34739863 Clinical Trial.